Press Releases

2021 Total Product Bookings of $1.217 billion Full Year 2021 Revenues of $1.132 billion Ended Year with 151 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems Entered 2022 with Product Backlog of $1.254 billion Omnicell, Inc....

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the fourth quarter and full-year 2021, after market on Monday,...

Strategic acquisition of pharmacy technology solutions provider expands and deepens EnlivenHealth division’s footprint across key pharmacy segments Accelerates Software-as-a-Service (“SaaS”) technology roadmap Omnicell, Inc. (Nasdaq:OMCL), a leading...

Addition of specialty pharmacy management services expands Advanced Services portfolio to support access to and management of complex medications Expected to be accretive to Omnicell’s non-GAAP EBITDA first quarter of 2023 Omnicell, Inc....

Strategic acquisition of leading specialty pharmacy management services provider supports the Autonomous Pharmacy vision and expands Omnicell’s Advanced Services portfolio Addresses significant need for access to and management of complex...

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conferences: Randall Lipps, Omnicell Chairman,...

Automated Controlled Substance Dispenser to accommodate Fresenius Kabi Simplist® MicroVault® Pre-filled Syringes Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and...

First Veterans Affairs facility to implement automation and technology-enabled services to support more cost-effective workflows and enhance pharmacy operations Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of...

GAAP and non-GAAP revenues of $296 million GAAP net income per diluted share of $0.61 Non-GAAP net income per diluted share of $1.08 Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of...

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the third quarter of 2021 before the open of the market on Tuesday,...

Expands nationwide footprint of retail pharmacy customers, adding industry-leading financial management, analytics, and population health solutions to EnlivenHealth division offering Addition of SaaS solutions accelerates EnlivenHealth’s innovation...

Access to expanded engineering resources will accelerate innovation for the Company’s cloud-based solutions portfolio Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and...

New capabilities focus on superior customer experience and innovation to drive maximum value sooner; deliver improved workflow efficiency, expanded automation, and enhanced medication management intelligence Omnicell, Inc. (Nasdaq:OMCL), a leading...

End-to-End Medication Management Platform Fulfills Journey to Fully Autonomous Pharmacy Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that...

Record revenues of $273 million GAAP net income per diluted share of $0.43 Record non-GAAP net income per diluted share of $0.97 Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare...

Strategic acquisition of leading pharmacy SaaS solutions provider supports the Autonomous Pharmacy vision and expands Omnicell’s Advanced Services portfolio Accelerates innovation roadmap for EnlivenHealth division with addition of SaaS solutions...